Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$160.79−0.31 (-0.19%)
Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –
Novartis Non-IFRS Free Cash Flow: $17,596M in FY2025, up 8.3% from a year earlier.
Latest, FY2025
17,596
Period ended Dec 31, 2025
Change on a year earlier
+8.3%
16,253 in FY2024
History
2 years
Since FY2024
Sources
1
Novartis Form 6-K (0001114448-26-000007)
Where the FY2025 figure comes from
“|| Free cash flow | 1 655 | 3 635 | -54 | 17 596 | 16 253 | 8”
Source: Novartis Form 6-K (0001114448-26-000007) ↗
Reported in Form 6-K (Free cash flow reconciliation).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Non-IFRS Free Cash Flow ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 17,596 | +8.3% | Novartis Form 6-K (0001114448-26-000007) ↗ |
| FY2024 | Dec 31, 2024 | 16,253 | – | Novartis Form 6-K (0001114448-26-000007) ↗ |
Cite this data
StockData. (2026). Novartis Non-IFRS Free Cash Flow ($M), annual FY2024–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/non-ifrs-fcf
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.